- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Ide-cel is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells.1,2 The ide-cel CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, CD3-zeta T-cell activation domain, and a 4-1BB domain hypothesized to increase T-cell activation, proliferation, and persistence.1,3-5 Ide-cel CAR T cells are proposed to recognize and bind BCMA on the surface of plasma cells leading to apoptosis.6,7
Ide-cel, an investigational CAR T therapy, is proposed to target BCMA on plasma cells.
An investigational anti-BCMA (B-cell maturation antigen) CAR-T cell therapy that is being developed for the treatment of multiple myeloma by Celgene in collaboration with bluebird bio.
In vitro experiments have shown that ide-cel has displayed activity against BCMA-expressing multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and plasmacytoma cell lines.8 Preclinical studies have demonstrated that anti-BCMA CAR T cells secrete cytokines following engagement of BCMA-expressing target cells.9